Jacobs Levy Equity Management, Inc Halozyme Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 898,192 shares of HALO stock, worth $62.9 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
898,192
Previous 1,002,619
10.42%
Holding current value
$62.9 Million
Previous $52.2 Million
26.3%
% of portfolio
0.28%
Previous 0.22%
Shares
15 transactions
Others Institutions Holding HALO
# of Institutions
666Shares Held
128MCall Options Held
626KPut Options Held
455K-
Black Rock Inc. New York, NY17.6MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$814 Million0.01% of portfolio
-
State Street Corp Boston, MA5.02MShares$351 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.29MShares$230 Million0.16% of portfolio
-
Invesco Ltd. Atlanta, GA3.25MShares$227 Million0.04% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...